private:rognebioscience-2
|
2660571
|
May 31st, 2019 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
May 31st, 2019 01:53PM
|
May 31st, 2019 01:53PM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
Open
|
|
Open
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Mar 23rd, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
34
|
0.00
|
Open
|
Biotechnology
|
Mar 23rd, 2017 10:51AM
|
Mar 23rd, 2017 10:51AM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 17th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation. Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis. Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals. For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 16th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 15th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 14th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 13th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 12th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 11th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|
private:rognebioscience-2
|
2660571
|
Feb 10th, 2018 12:00AM
|
Rogne Bioscience, Inc.
|
35
|
0.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
The company wound down all its research and development activities at the end of 2015, and dissolved the corporation in May 2016. The intellectual property relating to the Rogne program has been transferred to Oxford’s technology licensing organization, Oxford University Innovation.
Rogne Bioscience is an early stage start-up developing a first-in-class, anti-inflammatory human peptide as a topically applied treatment for psoriasis.
Rogne’s lead molecule is a potent, naturally-occurring peptide that acts as the body’s own “off-switch” in inflammation. Our peptide reduces IL-23, the key inflammatory cytokine in psoriasis, and will offer a superior topical therapy option with equivalent efficacy to injected biologics but without side effects to the 6 million mild-to-moderate U.S. patients who can spend up to $1500/yr for branded topicals.
For more information, contact us at info@rognebioscience.com
|
|
|
|
|
|
|
|
|
|
Rogne Bioscience
|
|
Pharmaceuticals & Biotechnology
|